Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 12, 2026, 10:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–15 of 15 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Differin® Clear all
Completed Phase 2 Interventional Results available

Adapalene Gel 0.3% in the Treatment of Atrophic Acne Scars

NCT01213199
View directory record Official record
Conditions
Acne Scars
Interventions
Adapalene
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Sep 12, 2026, 10:36 PM EDT
Completed Phase 3 Interventional

Bioequivalence Study of Adapalene Gel 0.3% in Subjects With Facial Acne Vulgaris

NCT03650361
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Adapalene Gel 0.3%, Differin 0.3% Topical Gel, Adapalene Gel 0.3% Vehicle Placebo
Drug
Lead sponsor
Aleor Dermaceuticals Limited
Industry
Eligibility
12 Years to 40 Years
Enrollment
755 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
9
States / cities
Sherman Oaks, California • Brandon, Florida • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2019 · Synced Sep 12, 2026, 10:36 PM EDT
Completed Phase 4 Interventional Results available

Analysis of Adherence in Subjects Undergoing Differin Gel, 0.1% Treatment of Moderate to Severe Acne Vulgaris

NCT00696449
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Adapalene, frequent visits, electronic reminder, Parent reminder, Standard of care
Drug · Behavioral
Lead sponsor
Wake Forest University
Other
Eligibility
13 Years to 18 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 9, 2018 · Synced Sep 12, 2026, 10:36 PM EDT
Active, not recruiting Early Phase 1 Interventional

Experience With Topical Acne Treatment

NCT05582434
View directory record Official record
Conditions
Acne
Interventions
clindamycin phosphate 1.2%/adapalene 0.15%/BPO 3.1% gel, adapalene 0.3%/BPO 2.5% gel and compounded clindamycin phosphate 1.2% gel, Compounded BPO 2.5% gel, adapalene 0.1% gel, and compounded clindamycin phosphate 1.2% gel
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 85 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Sep 12, 2026, 10:36 PM EDT
Completed Phase 4 Interventional

Analysis of Adherence & Associated Factors in Teenagers Undergoing Treatment of Acne Vulgaris With Differin® Gel 0.1%

NCT00437151
View directory record Official record
Conditions
Acne
Interventions
More frequent than normal office visits, Electronic reminders (voice, e-mail, text messages), Parenteral involvement / intervention reminders, No intervention or reminders
Other
Lead sponsor
Galderma R&D
Industry
Eligibility
13 Years to 18 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Sep 12, 2026, 10:36 PM EDT
Terminated Phase 4 Interventional Results available

Safety and Efficacy of Tazarotene Cream 0.1% Compared With Adapalene Gel 0.3% in the Treatment of Moderate to Severe Facial Acne Vulgaris

NCT00829049
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Tazarotene Cream 0.1%, Adapalene
Drug
Lead sponsor
Allergan
Industry
Eligibility
12 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Fremont, California
Source: ClinicalTrials.gov public record
Updated Sep 11, 2012 · Synced Sep 12, 2026, 10:36 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

A Study Comparing Adapalene Gel 0.1% and to Differin Gel in the Treatment of Acne Vulgaris

NCT04797793
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Adapalene Gel 0.1%, Placebo Control, Differin® Gel (Adapalene 0.1%, Galderma)
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
978 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 31, 2021 · Synced Sep 12, 2026, 10:36 PM EDT
Completed Phase 4 Interventional Results available

Pharmacokinetic Study to Compare the Systemic Exposure of Differin® Gel, 0.3% or Differin® Gel, 0.1%

NCT00660985
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Adapalene
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years to 35 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
2
States / cities
Austin, Texas • College Station, Texas
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Sep 12, 2026, 10:36 PM EDT
Completed Phase 4 Interventional

Differin® Gel x12 Wks vs Tazorac® Cream x12 Wks vs Differin® x6 Wks Switched to Tazorac® x6 Wks for Treatment of Acne

NCT00469755
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Adapalene Gel, 0.1%, Tazarotene Cream, 0.1%, Adapalene Gel, 0.1% + Tazarotene Cream, 0.1%
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years to 35 Years
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
12
States / cities
San Diego, California • Detroit, Michigan • Fridley, Minnesota + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Sep 12, 2026, 10:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Tolerability Comparison of Differin® Cream 0.1% Versus Differin® Lotion 0.1% in Subjects With Healthy Skin

NCT01046396
View directory record Official record
Conditions
Skin Manifestations
Interventions
adapalene cream 0.1% and adapalene lotion 0.1%, adapalene lotion 0.1%
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Colorado Springs, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 31, 2022 · Synced Sep 12, 2026, 10:36 PM EDT
Completed Phase 4 Interventional Results available

A Study Comparing Aczone® Plus Differin® Versus Duac® Plus Differin® in Patients With Severe Facial Acne

NCT01231334
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Dapsone plus Adapalene, Clindamycin/benzoyl peroxide plus Adapalene
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Jul 26, 2012 · Synced Sep 12, 2026, 10:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Tolerability Comparison Between Differin® Cream 0.1% Versus Differin® Lotion 0.1% in Subjects With Healthy Skin

NCT01046565
View directory record Official record
Conditions
Skin Manifestations
Interventions
adapalene cream 0.1%, adapalene lotion 0.1%
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Carrollton, Texas
Source: ClinicalTrials.gov public record
Updated Aug 24, 2022 · Synced Sep 12, 2026, 10:36 PM EDT
Completed Phase 4 Interventional Results available

Combination Therapy With Differin® Gel 0.3% and Duac® (Clindamycin/Benzoyl Peroxide Gel) in Subjects With Acne Vulgaris

NCT00671749
View directory record Official record
Conditions
Acne Vulgaris
Interventions
adapalene gel, 0.3%, clindamycin/benzoyl peroxide gel
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years to 35 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
4
States / cities
Sacramento, California • Louisville, Kentucky • Warren, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2022 · Synced Sep 12, 2026, 10:36 PM EDT
Completed Phase 1 Interventional

Bioequivalence of Adapalene Topical Gel in Patients With Acne Vulgaris

NCT01182636
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Adapalene, Differin®, Placebo
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
12 Years to 40 Years
Enrollment
601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
20
States / cities
Little Rock, Arkansas • Los Angeles, California • Denver, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2010 · Synced Sep 12, 2026, 10:36 PM EDT
Completed Phase 3 Interventional Results available

Adapalene Gel 0.3% Versus Tretinoin 0.05% Emollient Cream for Treatment of Photodamage

NCT00647556
View directory record Official record
Conditions
Photoaging
Interventions
adapalene gel, 0.3%, tretinoin 0.05% emollient cream
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
40 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 31, 2022 · Synced Sep 12, 2026, 10:36 PM EDT